An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.
Immune agents old and new are trying to make a splash in what could turn into a billion-dollar market.
This year’s AACR meeting promises a surprising amount of clinical data relevant to biopharma investors.
EQRX tears up plans to challenge US PD-(L)1 players on price, and switches focus to two non-discounted small molecules.
Fianlimab maintains its leading activity, but more Opdualag competition is not far behind.
The discontinuation of amcenestrant piles more pressure on the group’s chief executive, Paul Hudson.